Comparison of Healthcare Resource Utilization (HRU) and Costs Related to Pleural Effusion (PE) between Patients Newly Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Dasatinib Or Nilotinib as First-Line Therapy in the United States

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

5-2018

DOI

10.1016/j.jval.2018.04.176

Journal Title

Value in Health

Department

Medicine

This document is currently not available here.

Share

COinS